In patients with no indication for anticoagulation after TAVR, rivaroxaban increased adverse events vs antiplatelets

Ann Intern Med. 2020 Apr 21;172(8):JC40. doi: 10.7326/ACPJ202004210-040.
No abstract available

Publication types

  • Comment

MeSH terms

  • Anticoagulants
  • Factor Xa Inhibitors
  • Humans
  • Rivaroxaban*
  • Transcatheter Aortic Valve Replacement*

Substances

  • Anticoagulants
  • Factor Xa Inhibitors
  • Rivaroxaban